Citations (62)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (13)
R. Freynhagen, C. Elling, T. Radic, M. Sohns, H. Liedgens, D. James, R. McCool & M. Edwards. (2021) Safety of tapentadol compared with other opioids in chronic pain treatment: network meta-analysis of randomized controlled and withdrawal trials. Current Medical Research and Opinion 37:1, pages 89-100.
Read now
Read now
Hans G Kress & Flaminia Coluzzi. (2019) Tapentadol in the management of cancer pain: current evidence and future perspectives. Journal of Pain Research 12, pages 1553-1560.
Read now
Read now
Anthony H Dickenson & Hans G Kress. (2019) Tapentadol: a new option for the treatment of cancer and noncancer pains. Journal of Pain Research 12, pages 1509-1511.
Read now
Read now
M Cascella, CA Forte, S Bimonte, G Esposito, C Romano, R Costanzo, A Morabito & A Cuomo. (2019) Multiple effectiveness aspects of tapentadol for moderate–severe cancer-pain treatment: an observational prospective study. Journal of Pain Research 12, pages 117-125.
Read now
Read now
Satoshi Inoue, Yoji Saito, Satoru Tsuneto, Etsuko Aruga, Azusa Ide & Yasuyuki Kakurai. (2017) A randomized, double-blind study of hydromorphone hydrochloride extended-release tablets versus oxycodone hydrochloride extended-release tablets for cancer pain: efficacy and safety in Japanese cancer patients (EXHEAL: a Phase III study of EXtended-release HydromorphonE for cAncer pain reLief). Journal of Pain Research 10, pages 1953-1962.
Read now
Read now
Sebastiano Mercadante. (2017) The role of tapentadol as a strong opioid in cancer pain management: a systematic and critical review. Current Medical Research and Opinion 33:11, pages 1965-1969.
Read now
Read now
Nalini Vadivelu, Alice Kai, Benjamin Maslin, Gopal Kodumudi, Aron Legler & Jack M Berger. (2015) Tapentadol extended release in the management of peripheral diabetic neuropathic pain. Therapeutics and Clinical Risk Management 11, pages 95-105.
Read now
Read now
Flaminia Coluzzi, Robert B Raffa, Joseph Pergolizzi, Alessandra Rocco, Pamela Locarini, Natalia Cenfra, Giuseppe Cimino & Consalvo Mattia. (2015) Tapentadol prolonged release for patients with multiple myeloma suffering from moderate-to-severe cancer pain due to bone disease. Journal of Pain Research 8, pages 229-238.
Read now
Read now
Artur Schikowski, Doris Krings & Karla Schwenke. (2015) Tapentadol prolonged release for severe chronic cancer-related pain: effectiveness, tolerability, and influence on quality of life of the patients. Journal of Pain Research 8, pages 1-8.
Read now
Read now
Bishal Gyawali, Naomi Hayashi, Hiroaki Tsukuura, Kazunori Honda, Tomoya Shimokata & Yuichi Ando. (2015) Opioid-induced constipation. Scandinavian Journal of Gastroenterology 50:11, pages 1331-1338.
Read now
Read now
Sebastiano Mercadante. (2015) The use of opioids for treatment of cancer pain. Expert Opinion on Pharmacotherapy 16:3, pages 389-394.
Read now
Read now
Sebastiano Mercadante, Giampiero Porzio, Claudio Adile, Federica Aielli, Andrea Cortegiani, Anthony Dickenson & Alessandra Casuccio. (2014) Tapentadol at medium to high doses in patients previously receiving strong opioids for the management of cancer pain. Current Medical Research and Opinion 30:10, pages 2063-2068.
Read now
Read now
Keiichiro Imanaka, Yushin Tominaga, Mila Etropolski, Ilse Van Hove, Masaki Ohsaka, Mikio Wanibe, Keiichiro Hirose & Taka Matsumura. (2014) Adverse event reporting in the recent study by Imanaka et al. describing the efficacy and safety of tapentadol extended release for tumor-related pain. Current Medical Research and Opinion 30:9, pages 1909-1910.
Read now
Read now
Articles from other publishers (49)
Alessandra Oliveira Silva, Danielle Aparecida de Oliveira Marrafon, Ana Flávia Amorim, Carlos Marcelo de Barros, Ricardo Radighieri Rascado, Carla Speroni Ceron, Tiago Marques dos Reis, Márcia Helena MIranda Cardoso Podestá, Daniel Augusto de Faria Almeida, Larissa Helena Torres & Marília Gabriella Alves Goulart Pereira. (2023) Tapentadol, an opioid as a strategy for the treatment of chronic pain? A narrative review. Journal of Pharmaceutical and Biological Sciences 11:1, pages 18-25.
Crossref
Crossref
Lilli Stephenson, Corinna van den Heuvel, Melissa Humphries, Timothy Scott & Roger W Byard. (2023) Increased incidence of mixed drug toxicity deaths involving tapentadol – A forensic study. Medicine, Science and the Law.
Crossref
Crossref
Jason W. Boland. (2023) Tapentadol for the management of cancer pain in adults: an update. Current Opinion in Supportive & Palliative Care 17:2, pages 90-97.
Crossref
Crossref
Hironori MawatariTakuya ShinjoTatsuya MoritaHiroyuki KoharaKinomi Yomiya. (2022) Revision of Pharmacological Treatment Recommendations for Cancer Pain: Clinical Guidelines from the Japanese Society of Palliative Medicine. Journal of Palliative Medicine 25:7, pages 1095-1114.
Crossref
Crossref
Ji Yoon Jung, Hong Jae Chon, Young Jin Choi, Sang Eun Yeon, Seok Young Choi & Kyung Hee Lee. (2022) A prospective, multicenter, open-label study of the clinical efficacy of tapentadol extended-release in the treatment of cancer-related pain and improvement in the quality of life of opioid-naïve or opioid-resistant patients. Supportive Care in Cancer 30:7, pages 6103-6112.
Crossref
Crossref
Joseph Pergolizzi, Peter Magnusson, Flaminia Coluzzi, Frank Breve, Jo Ann K LeQuang & Giustino Varrassi. (2022) Multimechanistic Single-Entity Combinations for Chronic Pain Control: A Narrative Review. Cureus.
Crossref
Crossref
Mia Schmidt-Hansen, Michael I Bennett, Stephanie Arnold, Nathan Bromham, Jennifer S Hilgart, Andrew J Page & Yuan Chi. (2022) Oxycodone for cancer-related pain. Cochrane Database of Systematic Reviews 2022:6.
Crossref
Crossref
. 2022. Arzneimitteltherapie in der Palliativmedizin. Arzneimitteltherapie in der Palliativmedizin
511
774
.
Patrice Forget & Mathieu Vermeersch. (2020) To what extent are we confident that tapentadol induces less constipation and other side effects than the other opioids in chronic pain patients? a confidence evaluation in network meta-analysis. British Journal of Pain 15:4, pages 380-387.
Crossref
Crossref
Lucien Roulet, Victoria Rollason, Jules Desmeules & Valérie Piguet. (2021) Tapentadol Versus Tramadol: A Narrative and Comparative Review of Their Pharmacological, Efficacy and Safety Profiles in Adult Patients. Drugs 81:11, pages 1257-1272.
Crossref
Crossref
Bart J Morlion, César Margarit, Imane Wild, Ravi Karra, Hiltrud Liedgens, Melanie Sohns & Gabriele Finco. (2021) Bone fractures in patients using tapentadol or oxycodone: an exploratory US claims database study. Pain Management 11:1, pages 39-47.
Crossref
Crossref
Shoichiro Sazuka & Toshiya Koitabashi. (2020) Tapentadol is effective in the management of moderate-to-severe cancer-related pain in opioid-naïve and opioid-tolerant patients: a retrospective study. Journal of Anesthesia 34:6, pages 834-840.
Crossref
Crossref
Shigeki Yamaguchi, Eiji Uchida, Takaaki Terahara, Koji Okawa, Fumitaka Hashimoto & Yusuke Tanaka. (2020) Efficacy and Safety of Fentanyl Citrate Patch, Including a Low-Dose 0.5 mg Formulation, in Opioid-Naïve Patients with Cancer Pain. Clinical Drug Investigation 40:11, pages 1041-1052.
Crossref
Crossref
Tara SanftCrystal S. DenlingerSaro ArmenianK. Scott BakerGregory BroderickWendy Demark-WahnefriedDebra L. FriedmanMindy GoldmanMelissa HudsonNazanin KhakpourDivya KouraRobin M. LallyTerry S. LangbaumAllison L. McDonoughMichelle MeliskoKathi MooneyHalle C.F. MooreJavid J. MoslehiTracey O’ConnorLinda OverholserElectra D. PaskettLindsay PetersonWilliam PirlM. Alma RodriguezKathryn J. RuddySophia SmithKaren L. SyrjalaAmye TevaarwerkSusan G. UrbaPhyllis Zee, Nicole R. McMillianDeborah A. Freedman-Cass. (2019) NCCN Guidelines Insights: Survivorship, Version 2.2019. Journal of the National Comprehensive Cancer Network 17:7, pages 784-794.
Crossref
Crossref
Emma D. Deeks. (2018) Tapentadol Prolonged Release: A Review in Pain Management. Drugs 78:17, pages 1805-1816.
Crossref
Crossref
Robert B. Raffa, Christian Elling & Thomas M. Tzschentke. (2018) Does ‘Strong Analgesic’ Equal ‘Strong Opioid’? Tapentadol and the Concept of ‘µ-Load’. Advances in Therapy 35:10, pages 1471-1484.
Crossref
Crossref
Jessie S Channell & Stephan Schug. (2018) Toxicity of tapentadol: a systematic review. Pain Management 8:5, pages 327-339.
Crossref
Crossref
Renata Zajączkowska, Barbara Przewłocka, Magdalena Kocot-Kępska, Joanna Mika, Wojciech Leppert & Jerzy Wordliczek. (2018) Tapentadol – A representative of a new class of MOR-NRI analgesics. Pharmacological Reports 70:4, pages 812-820.
Crossref
Crossref
Mia Schmidt-Hansen, Michael I Bennett, Stephanie Arnold, Nathan Bromham & Jennifer S Hilgart. (2018) Efficacy, tolerability and acceptability of oxycodone for cancer-related pain in adults: an updated Cochrane systematic review. BMJ Supportive & Palliative Care 8:2, pages 117-128.
Crossref
Crossref
Satoshi Inoue, Yoji Saito, Satoru Tsuneto, Etsuko Aruga, Hiroshi Takahashi & Mitsutoshi Uemori. (2018) A randomized, double-blind, non-inferiority study of hydromorphone hydrochloride immediate-release tablets versus oxycodone hydrochloride immediate-release powder for cancer pain: efficacy and safety in Japanese cancer patients. Japanese Journal of Clinical Oncology 48:6, pages 542-547.
Crossref
Crossref
Yosuke Sugiyama, Tomoya Kataoka, Yoshihiko Tasaki, Yuki Kondo, Noriko Sato, Taku Naiki, Nobuhiro Sakamoto, Tatsuo Akechi & Kazunori Kimura. (2018) Efficacy of tapentadol for first-line opioid-resistant neuropathic pain in Japan. Japanese Journal of Clinical Oncology 48:4, pages 362-366.
Crossref
Crossref
. 2018. Arzneimitteltherapie in der Palliativmedizin. Arzneimitteltherapie in der Palliativmedizin
447
696
.
Ariane Stollenwerk, Melanie Sohns, Fabian Heisig, Christian Elling & Detlef von Zabern. (2017) Review of Post-Marketing Safety Data on Tapentadol, a Centrally Acting Analgesic. Advances in Therapy 35:1, pages 12-30.
Crossref
Crossref
R. van der Schrier, K. Jonkman, M. van Velzen, E. Olofsen, A M Drewes, A. Dahan & M. Niesters. (2017) An experimental study comparing the respiratory effects of tapentadol and oxycodone in healthy volunteers. British Journal of Anaesthesia 119:6, pages 1169-1177.
Crossref
Crossref
Alberto Carmona-Bayonas, Paula Jiménez Fonseca & Juan Virizuela Echaburu. (2017) Tapentadol for Cancer Pain Management: A Narrative Review. Pain Practice 17:8, pages 1075-1088.
Crossref
Crossref
Mia Schmidt-Hansen, Michael I Bennett, Stephanie Arnold, Nathan Bromham & Jennifer S Hilgart. (2017) Oxycodone for cancer-related pain. Cochrane Database of Systematic Reviews 2019:3.
Crossref
Crossref
Zengdong Meng, Jing Yu, Michael Acuff, Chong Luo, Sanrong Wang, Lehua Yu & Rongzhong Huang. (2017) Tolerability of Opioid Analgesia for Chronic Pain: A Network Meta-Analysis. Scientific Reports 7:1.
Crossref
Crossref
Liping Zhang, Xiaoyu Yan, Sayori Nobe, Peter Zannikos, Mila Etropolski & Partha Nandy. (2016) Quantifying the Exposure of Tapentadol Extended Release in Japanese Patients with Cancer Pain and Bridging Tapentadol Pharmacokinetics Across Populations Using a Modeling Approach. Clinical Drug Investigation 37:3, pages 273-283.
Crossref
Crossref
H.G. Kress, E.D. Koch, H. Kosturski, A. Steup, K. Karcher, C. Dogan, M. Etropolski & M. Eerdekens. (2016) Direct conversion from tramadol to tapentadol prolonged release for moderate to severe, chronic malignant tumour‐related pain. European Journal of Pain 20:9, pages 1513-1518.
Crossref
Crossref
Emma D. Deeks & Katherine A. Lyseng-Williamson. (2016) Oxycodone prolonged release: a guide to its use in the EU. Drugs & Therapy Perspectives 32:9, pages 363-368.
Crossref
Crossref
Ralf Baron, Jan‐Peter Jansen, Andreas Binder, Manuel Pombo‐Suarez, Lieven Kennes, Matthias Müller, Dietmar Falke & Ilona Steigerwald. (2015)
Tolerability, Safety, and Quality of Life with Tapentadol Prolonged Release (
PR
) Compared with Oxycodone/Naloxone
PR
in Patients with Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open‐label, Phase 3b/4 Trial
. Pain Practice 16:5, pages 600-619.
Crossref
Crossref
Ralf Baron, Rudolf Likar, Emilio Martin‐Mola, Francisco J. Blanco, Lieven Kennes, Matthias Müller, Dietmar Falke & Ilona Steigerwald. (2015)
Effectiveness of Tapentadol Prolonged Release (
PR
) Compared with Oxycodone/Naloxone
PR
for the Management of Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open‐Label, Phase 3b/4 Study
. Pain Practice 16:5, pages 580-599.
Crossref
Crossref
Tomoe Fukunaga, Tatsuo Kamikawa, Masahiro Senta & Shinichi Ishikawa. (2016) Retrospective Analysis Based on Clinical Experience of Tapentadol in Cancer Pain Management. Palliative Care Research 11:1, pages 306-310.
Crossref
Crossref
Keiichiro Imanaka, Takashi Yoshimura, Yushin Tominaga, Hiromi Koga & Keiichiro Hirose. (2016) A Multicenter, Open-label Study of Tapentadol Extended-release Tablets in Opioid-naïve and Opioid-switching Subjects with Moderate to Severe Cancer Pain. Palliative Care Research 11:2, pages 147-155.
Crossref
Crossref
Keiichiro Imanaka, Takashi Yoshimura, Yushin Tominaga, Hiromi Koga & Keiichiro Hirose. (2016) 8-week Safety Profile of Tapentadol Extended Release Tablets Switched from Other Opioids for Well-controlled, Moderate to Severe, Chronic Malignant Tumor-related Pain: Constipation, Nausea, Vomiting and Somnolence. Palliative Care Research 11:1, pages 116-122.
Crossref
Crossref
Escarlata López Ramírez, D. M. Muñoz Carmona, J. Contreras Martínez & A. de la Torre Luque. (2016) Tapentadol in the management of opioid-naïve patients with cancer pain. Revista de la Sociedad Española del Dolor 23.
Crossref
Crossref
Robert Buynak, Stephen A. Rappaport, Kevin Rod, Pierre Arsenault, Fabian Heisig, Christine Rauschkolb & Mila Etropolski. (2015) Long-term Safety and Efficacy of Tapentadol Extended Release Following up to 2 Years of Treatment in Patients With Moderate to Severe, Chronic Pain: Results of an Open-label Extension Trial. Clinical Therapeutics 37:11, pages 2420-2438.
Crossref
Crossref
Philip J Wiffen, Sheena Derry, Katrien Naessens & Rae Frances Bell. (2015) Oral tapentadol for cancer pain. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Hongki Lee, Virginia De Vito, Mario Giorgi & Hyoin Yun. (2015) Synergistic interaction between tapentadol and flupirtine in the rat orafacial formalin test. European Journal of Pharmacology 762, pages 350-356.
Crossref
Crossref
Ralf Baron, Emilio Martin‐Mola, Matthias Müller, Cecile Dubois, Dietmar Falke & Ilona Steigerwald. (2014)
Effectiveness and Safety of Tapentadol Prolonged Release (
PR
) Versus a Combination of Tapentadol
PR
and Pregabalin for the Management of Severe, Chronic Low Back Pain With a Neuropathic Component: A Randomized, Double‐blind, Phase 3b Study
. Pain Practice 15:5, pages 455-470.
Crossref
Crossref
Mia Schmidt-Hansen, Michael I Bennett, Stephanie Arnold, Nathan Bromham & Jennifer S Hilgart. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Sherwyn Schwartz, Mila S. Etropolski, Douglas Y. Shapiro, Christine Rauschkolb, Aaron I. Vinik, Bernd Lange, Kimberly Cooper, Ilse Van Hove & Juergen Haeussler. (2014) A Pooled Analysis Evaluating the Efficacy and Tolerability of Tapentadol Extended Release for Chronic, Painful Diabetic Peripheral Neuropathy. Clinical Drug Investigation 35:2, pages 95-108.
Crossref
Crossref
S. Falk, R. Patel, A. Heegaard, S. Mercadante & A.H. Dickenson. (2015) Spinal neuronal correlates of tapentadol analgesia in cancer pain: A back-translational approach. European Journal of Pain 19:2, pages 152-158.
Crossref
Crossref
Deepika Thakur, Sara Dickerson, Mohit Kumar Bhutani & Rod Junor. (2015) Impact of Prolonged-release Oxycodone/Naloxone on Outcomes Affecting Patients' Daily Functioning in Comparison With Extended-release Tapentadol: A Systematic Review. Clinical Therapeutics 37:1, pages 212-224.
Crossref
Crossref
Manuel J. Sánchez del Águila, Michael Schenk, Kai-Uwe Kern, Tanja Drost & Ilona Steigerwald. (2015) Practical Considerations for the Use of Tapentadol Prolonged Release for the Management of Severe Chronic Pain. Clinical Therapeutics 37:1, pages 94-113.
Crossref
Crossref
. 2015. Arzneimitteltherapie in der Palliativmedizin. Arzneimitteltherapie in der Palliativmedizin
417
651
.
Sarah Falk, Kirsty Bannister & Anthony H Dickenson. (2014) Cancer pain physiology. British Journal of Pain 8:4, pages 154-162.
Crossref
Crossref
Keiichiro Imanaka, Yushin Tominaga, Mila Etropolski, Hiroki Ohashi, Keiichiro Hirose & Taka Matsumura. (2014) Ready Conversion of Patients with Well-Controlled, Moderate to Severe, Chronic Malignant Tumor–related Pain on Other Opioids to Tapentadol Extended Release. Clinical Drug Investigation 34:7, pages 501-511.
Crossref
Crossref
Philip J Wiffen, Sheena Derry & R Andrew Moore. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.